Literature DB >> 1622860

Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum.

R S Benjamin1, S P Chawla, C H Carrasco, A K Raymond, J A Murray, T Armen, S Patel, S Wallace, A Ayala, N E Papadopoulos.   

Abstract

Ninety-seven patients with primary osteosarcoma of the extremities, all age 16 or older, were treated with adriamycin, 90 mg/m2, continuous i.v. infusion over 96 h, followed by cis-platinum, 120-160 mg/m2 by intra-arterial infusion. The first 37 patients, treated from 1979-1982, had a 59% complete response rate and a 54% 5-year continuous disease free survival (CDFS). Patients with complete response had an 85% 5-year CDFS compared with 13% for patients with partial and poor response. Patients treated between 1983-1988 with an intensified regimen have a 68% complete response rate and a 69% 3-year CDFS. Those who did not achieve complete remission were switched to an alternating chemotherapy program emphasizing the use of high-dose methotrexate. Limb salvage has been accomplished in 59% of patients in the first group and 80% in patients of the second group. Preoperative chemotherapy allows informed decisions to be made in postoperative management which can influence overall cure rates. Long-term follow-up is essential before final interpretation of the data.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622860     DOI: 10.1093/annonc/3.suppl_2.s3

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

1.  Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.

Authors:  H Assi; G Missenard; P Terrier; C Le Pechoux; S Bonvalot; D Vanel; J B Meric; T Tursz; A Lecesne
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

2.  Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.

Authors:  Ronald R Hugate; Ross M Wilkins; Cynthia M Kelly; Walt Madsen; Ioana Hinshaw; Anne B Camozzi
Journal:  Clin Orthop Relat Res       Date:  2008-04-25       Impact factor: 4.176

3.  Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1).

Authors:  Barry P Pereira; Yefang Zhou; Anurag Gupta; David T Leong; Khin Zarchi Aung; Ling Ling; Robert W H Pho; Mario Galindo; Manuel Salto-Tellez; Gary S Stein; Simon M Cool; Andre J van Wijnen; Saminathan S Nathan
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

4.  Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions.

Authors:  E S Hookway; Z Orosz; Y Uchihara; A Grigoriadis; A B Hassan; U Oppermann; N A Athanasou
Journal:  Clin Sarcoma Res       Date:  2017-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.